Who invested in Avedro

10 rounds we have observed, with the 14 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

BiotechHealthcare

Funding summaryUpdated 26 Oct 2026

$203Mraised across 10 rounds since 2009, from 10 sources

$10MVenture$6.3MVenture$13MVenture$25MSeries C$500KVenture$43MSeries D$6.5MDebt$32MSeries E$42MDebt$25MRound

Latest round: Round, $25MMay 2018
Biggest round: $43MSeries D · Mar 2013
Investors: 14

See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

20092011201320152017

$10MVenture$6.3MVenture$13MVenture$500KVenture$43MSeries D$6.5MDebt$32MSeries E$42MDebt$25MRound

First round: Venture, $10M
Biggest round: $43M
Usual gap between rounds: 12 months

The rounds

May 2018
Round$25M2 new1 returning
- InterWest Partners
- HealthQuest Capital
- Lilly Asia Ventures/ OrbiMed
Reported by FinSMEsSEC filing: $25M sold, first sale Apr 2018
Apr 2017
Debt$42M1 new1 returning
- InterWest Partners
- HealthQuest Capital/ OrbiMed
Reported by FinSMEsSEC filing: $12M sold, first sale Apr 2017
Nov 2015
Series E$32M2 new
- OrbiMed
- InterWest Partners
From a historical funding recordSEC filing: $17M sold, first sale Nov 2015
Nov 2014
Debt$6.5M
No investor was named in the report.
From a historical funding recordSEC filing: $6.5M sold, first sale Nov 2014
Mar 2013
Series D$43M6 new2 returning
Reported by boston.comSEC filing: $42M sold, first sale Mar 2013
Feb 2012
Venture$500K1 new1 returning
- SCP Vitalife Partners
- M. Carl Johnson
Reported by masshightech.comSEC filing: $26M sold, first sale Jun 2011
Jul 2011
Series C$25M2 new
- Aperture Venture Partners
- SCP Vitalife Partners
Reported by masshightech.comSEC filing: $26M sold, first sale Jun 2011
May 2011
Venture$13M
No investor was named in the report.
Reported by masshightech.comSEC filing: $13M sold, first sale Jul 2010
Jan 2011
Venture$6.3M
No investor was named in the report.
Reported by masshightech.comSEC filing: $6.3M sold, first sale Jul 2010
Apr 2009
Venture$10M
No investor was named in the report.
From a historical funding recordSEC filing: $10M sold, first sale Apr 2009

Founders and team

From Avedro's own website and the SEC filings it signed: 6 on the team.

Joseph E. GilliamPresident & Chief Operating Officer
Thomas W. BurnsChairman & Chief Executive Officer
Matt YoungSenior Vice President, Global Operations
Robert L. DavisSenior Vice President, General Counsel & Business Development
Tracy M. FoundsSenior Vice President, Global Quality and Medical Safety
Reza ZadnoExecutive Officer, Directori

On the board, as filediDonald ZurbayGarheng KongGilbert KlimanHongbo LuJonathan SilversteinJoseph MandatoRobert Palmisano

Who was in which round

The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.

Venture2011Series C2011Venture2012Series D2013Debt2014Series E2015Debt2017Round2018

InterWest Partners

SCP Vitalife PartnersAperture Venture Partners

OrbiMedFlagship Pioneering, LLCDe Novo Ventures

Prism Venture Partners

Third Point Ventures

Borealis Ventures

HealthQuest Capital

Everyone who backed them

InterWest PartnersVC firm3rounds

SCP Vitalife PartnersVC firm3rounds

Aperture Venture PartnersVC firm2rounds

OrbiMedPrivate equity1round

Flagship Pioneering, LLCVC firm1round

De Novo VenturesGrowth equity1round

Prism Venture PartnersVC firm1round

Third Point VenturesVC firm1round

Borealis VenturesVC firm1round

HealthQuest CapitalGrowth equity1round

Echelon VenturesVC firm1round

HealthQuest Capital/ OrbiMedno record of our own yet1round

Lilly Asia Ventures/ OrbiMedno record of our own yet1round

M. Carl Johnsonno record of our own yet1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Avedro

Who invested in Avedro?

Avedro's investors include InterWest Partners, SCP Vitalife Partners, Aperture Venture Partners, OrbiMed and Flagship Pioneering, LLC, and 9 more on record.